These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35467249)

  • 1. Hyperpolarized [1-
    Esfahani SA; Callahan C; Rotile NJ; Heidari P; Mahmood U; Caravan PD; Grant AK; Yen YF
    Mol Imaging Biol; 2022 Oct; 24(5):769-779. PubMed ID: 35467249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER3 PET Imaging Predicts Response to Pan Receptor Tyrosine Kinase Inhibition Therapy in Gastric Cancer.
    Esfahani SA; de Aguiar Ferreira C; Rotile NJ; Ataeinia B; Krishna S; Catalano OA; Caravan P; Yen YF; Heidari P; Mahmood U
    Mol Imaging Biol; 2023 Apr; 25(2):353-362. PubMed ID: 35962301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.
    Janjigian YY; Viola-Villegas N; Holland JP; Divilov V; Carlin SD; Gomes-DaGama EM; Chiosis G; Carbonetti G; de Stanchina E; Lewis JS
    J Nucl Med; 2013 Jun; 54(6):936-43. PubMed ID: 23578997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vivo Assessment of Ovarian Tumor Response to Tyrosine Kinase Inhibitor Pazopanib by Using Hyperpolarized
    Ravoori MK; Singh SP; Lee J; Bankson JA; Kundra V
    Radiology; 2017 Dec; 285(3):830-838. PubMed ID: 28707963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined hyperpolarized
    Hansen AE; Gutte H; Holst P; Johannesen HH; Rahbek S; Clemmensen AE; Larsen MME; Schøier C; Ardenkjaer-Larsen J; Klausen TL; Kristensen AT; Kjaer A
    Eur J Radiol; 2018 Jun; 103():6-12. PubMed ID: 29803387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multimodal assessment of in vivo metabolism with hyperpolarized [1-13C]MR spectroscopy and 18F-FDG PET imaging in hepatocellular carcinoma tumor-bearing rats.
    Menzel MI; Farrell EV; Janich MA; Khegai O; Wiesinger F; Nekolla S; Otto AM; Haase A; Schulte RF; Schwaiger M
    J Nucl Med; 2013 Jul; 54(7):1113-9. PubMed ID: 23596002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic Resonance Imaging Is More Sensitive Than PET for Detecting Treatment-Induced Cell Death-Dependent Changes in Glycolysis.
    Hesketh RL; Wang J; Wright AJ; Lewis DY; Denton AE; Grenfell R; Miller JL; Bielik R; Gehrung M; Fala M; Ros S; Xie B; Hu DE; Brindle KM
    Cancer Res; 2019 Jul; 79(14):3557-3569. PubMed ID: 31088837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous characterization of tumor cellularity and the Warburg effect with PET, MRI and hyperpolarized
    Hundshammer C; Braeuer M; Müller CA; Hansen AE; Schillmaier M; Düwel S; Feuerecker B; Glaser SJ; Haase A; Weichert W; Steiger K; Cabello J; Schilling F; Hövener JB; Kjær A; Nekolla SG; Schwaiger M
    Theranostics; 2018; 8(17):4765-4780. PubMed ID: 30279736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma.
    Chaumeil MM; Ozawa T; Park I; Scott K; James CD; Nelson SJ; Ronen SM
    Neuroimage; 2012 Jan; 59(1):193-201. PubMed ID: 21807103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous Hyperpolarized 13C-Pyruvate MRI and 18F-FDG PET (HyperPET) in 10 Dogs with Cancer.
    Gutte H; Hansen AE; Larsen MM; Rahbek S; Henriksen ST; Johannesen HH; Ardenkjaer-Larsen J; Kristensen AT; Højgaard L; Kjær A
    J Nucl Med; 2015 Nov; 56(11):1786-92. PubMed ID: 26338899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperpolarized [1-
    Rao Y; Gammon S; Zacharias NM; Liu T; Salzillo T; Xi Y; Wang J; Bhattacharya P; Piwnica-Worms D
    Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22378-22389. PubMed ID: 32839325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyruvate-lactate exchange and glucose uptake in human prostate cancer cell models. A study in xenografts and suspensions by hyperpolarized [1-
    van Heijster FHA; Heskamp S; Breukels V; Veltien A; Franssen GM; Jansen KCFJ; Boerman OC; Schalken JA; Scheenen TWJ; Heerschap A
    NMR Biomed; 2020 Oct; 33(10):e4362. PubMed ID: 32662543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperpolarized [1-
    Scroggins BT; Matsuo M; White AO; Saito K; Munasinghe JP; Sourbier C; Yamamoto K; Diaz V; Takakusagi Y; Ichikawa K; Mitchell JB; Krishna MC; Citrin DE
    Clin Cancer Res; 2018 Jul; 24(13):3137-3148. PubMed ID: 29599412
    [No Abstract]   [Full Text] [Related]  

  • 14. Simultaneous hyperpolarized (13)C-pyruvate MRI and (18)F-FDG-PET in cancer (hyperPET): feasibility of a new imaging concept using a clinical PET/MRI scanner.
    Gutte H; Hansen AE; Henriksen ST; Johannesen HH; Ardenkjaer-Larsen J; Vignaud A; Hansen AE; Børresen B; Klausen TL; Wittekind AM; Gillings N; Kristensen AT; Clemmensen A; Højgaard L; Kjær A
    Am J Nucl Med Mol Imaging; 2015; 5(1):38-45. PubMed ID: 25625025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring therapy with MEK inhibitor U0126 in a novel Wilms tumor model in Wt1 knockout Igf2 transgenic mice using 18F-FDG PET with dual-contrast enhanced CT and MRI: early metabolic response without inhibition of tumor growth.
    Flores LG; Yeh HH; Soghomonyan S; Young D; Bankson J; Hu Q; Alauddin M; Huff V; Gelovani JG
    Mol Imaging Biol; 2013 Apr; 15(2):175-85. PubMed ID: 22875335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDAC inhibition in glioblastoma monitored by hyperpolarized
    Radoul M; Najac C; Viswanath P; Mukherjee J; Kelly M; Gillespie AM; Chaumeil MM; Eriksson P; Delos Santos R; Pieper RO; Ronen SM
    NMR Biomed; 2019 Feb; 32(2):e4044. PubMed ID: 30561869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimodality In Vivo Imaging of Perfusion and Glycolysis in a Rat Model of C6 Glioma.
    Qi Q; Fox MS; Lim H; Bartha R; Scholl TJ; Hoffman L; Lee TY; Thiessen JD
    Mol Imaging Biol; 2021 Aug; 23(4):516-526. PubMed ID: 33534038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.
    Ma WW; Jacene H; Song D; Vilardell F; Messersmith WA; Laheru D; Wahl R; Endres C; Jimeno A; Pomper MG; Hidalgo M
    J Clin Oncol; 2009 Jun; 27(16):2697-704. PubMed ID: 19380450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Reduction of Glucose Consumption Is a Biomarker of Kinase Inhibitor Efficacy Which Can Be Reversed with GLUT1 Overexpression in Lung Cancer Cells.
    Ghezzi C; Perez S; Ryan K; Wong A; Chen BY; Damoiseaux R; Clark PM
    Mol Imaging Biol; 2023 Jun; 25(3):541-553. PubMed ID: 36284040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.
    Cullinane C; Dorow DS; Jackson S; Solomon B; Bogatyreva E; Binns D; Young R; Arango ME; Christensen JG; McArthur GA; Hicks RJ
    J Nucl Med; 2011 Aug; 52(8):1261-7. PubMed ID: 21764800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.